Latest publications
-
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
-
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
-
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH. et al, (2024), J Clin Oncol
-
Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response
Drennan P. et al, (2024), The Lancet Microbe
-
Assessing the Utility of ColabFold and AlphaMissense in Determining Missense Variant Pathogenicity for Congenital Myasthenic Syndromes.
Ryan-Phillips F. et al, (2024), Biomedicines, 12
Upcoming Seminars
-
Tuesday, 21 January 2025, 1pm to 2pm
Speakers: Professor Jean Soulier
-
Thursday, 23 January 2025, 12pm to 1pm
Speakers: Professor Nicky Whiffin
-
Wednesday, 29 January 2025, 1.30pm to 2.30pm
Speakers: Dr Simon Cleary
-
Thursday, 30 January 2025, 12pm to 1pm
Speakers: Prof Gavin Wright
-
Friday, 31 January 2025, 9.15am to 10.15am
Speakers: Dr Mariana Borsa
-
Tuesday, 04 February 2025, 1pm to 2pm
Speakers: Professor Jacob Corn